Dimensional Fund Advisors LP Has $69.34 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Dimensional Fund Advisors LP cut its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,669,287 shares of the company's stock after selling 156,747 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.43% of Moderna worth $69,344,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC grew its position in Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the last quarter. Geode Capital Management LLC boosted its stake in Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after purchasing an additional 171,774 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Moderna by 24.3% during the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after purchasing an additional 979,858 shares during the last quarter. Norges Bank acquired a new stake in shares of Moderna in the fourth quarter valued at $163,833,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Moderna by 9.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock valued at $97,472,000 after buying an additional 211,426 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Friday, March 21st. Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a report on Thursday, January 16th. Evercore ISI reduced their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday. Bank of America lowered their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. Finally, Morgan Stanley dropped their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Moderna has a consensus rating of "Hold" and a consensus price target of $53.95.

Moderna Stock Performance

MRNA stock traded down $1.23 during midday trading on Tuesday, hitting $26.61. 1,928,756 shares of the company's stock were exchanged, compared to its average volume of 7,404,843. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The company has a market cap of $10.29 billion, a PE ratio of -2.89 and a beta of 1.99. The stock's fifty day moving average price is $29.40 and its 200-day moving average price is $37.16.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same quarter in the previous year, the firm posted ($3.07) earnings per share. The business's revenue was down 35.3% on a year-over-year basis. On average, analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.